验证数据展示
经过测试的应用
| Positive WB detected in | MCF-7 cells, HEK-293 cells, HeLa cells |
| Positive IP detected in | HEK-293 cells |
| Positive IHC detected in | human liver cancer tissue, human liver tissue, mouse liver tissue Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0 |
推荐稀释比
| 应用 | 推荐稀释比 |
|---|---|
| Western Blot (WB) | WB : 1:500-1:3000 |
| Immunoprecipitation (IP) | IP : 0.5-4.0 ug for 1.0-3.0 mg of total protein lysate |
| Immunohistochemistry (IHC) | IHC : 1:250-1:1000 |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
产品信息
15428-1-AP targets Alpha Galactosidase A in WB, IHC, IF, IP, ELISA applications and shows reactivity with human, rat samples.
| 经测试应用 | WB, IP, IHC, ELISA Application Description |
| 文献引用应用 | WB, IHC, IF |
| 经测试反应性 | human, rat |
| 文献引用反应性 | human, rat |
| 免疫原 | Alpha Galactosidase A fusion protein Ag7609 种属同源性预测 |
| 宿主/亚型 | Rabbit / IgG |
| 抗体类别 | Polyclonal |
| 产品类型 | Antibody |
| 全称 | galactosidase, alpha |
| 别名 | Alpha D galactosidase A, Alpha galactosidase A, galactosidase, alpha |
| 计算分子量 | 49 kDa |
| 观测分子量 | 46-50 kDa |
| GenBank蛋白编号 | BC002689 |
| 基因名称 | GLA |
| Gene ID (NCBI) | 2717 |
| RRID | AB_10638002 |
| 偶联类型 | Unconjugated |
| 形式 | Liquid |
| 纯化方式 | Antigen affinity purification |
| UNIPROT ID | P06280 |
| 储存缓冲液 | PBS with 0.02% sodium azide and 50% glycerol , pH 7.3 |
| 储存条件 | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. |
背景介绍
GLA (Alpha-galactosidase A), also named as Melibiase or Agalsidase, belongs to the glycosyl hydrolase 27 family. It catalyzes the hydrolysis of terminal, non-reducing alpha-D-galactose residues in alpha-D-galactosides, including galactose oligosaccharides, galactomannans and galactolipids. The deficient activity of GLA can cause Fabry disease which is an X-linked inborn error of glycosphingolipid metabolis (PMID: 19287194). Enzyme replacement therapy (ERT) with GLA is currently the most effective therapeutic strategy for patients with Fabry disease (PMID: 20398385). In humans, GLA is synthesized as a 50 kDa precursor, which is further processed to a 46 kDa mature form of the protein (PMID: 9883849, 19387866). It also has a homodimer form with the molecular mass of 110 kDa (PMID: 17287429).
实验方案
| Product Specific Protocols | |
|---|---|
| WB protocol for Alpha Galactosidase A antibody 15428-1-AP | Download protocol |
| IHC protocol for Alpha Galactosidase A antibody 15428-1-AP | Download protocol |
| IP protocol for Alpha Galactosidase A antibody 15428-1-AP | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
发表文章
| Species | Application | Title |
|---|---|---|
J Extracell Vesicles Extracellular vesicles from recombinant cell factories improve the activity and efficacy of enzymes defective in lysosomal storage disorders.
| ||
Orphanet J Rare Dis Deep characterization of the anti-drug antibodies developed in Fabry disease patients, a prospective analysis from the French multicenter cohort FFABRY. | ||
Adv Mater Sequential Targeted Enzyme-Instructed Self-Assembly Supramolecular Nanofibers to Attenuate Intervertebral Disc Degeneration |
